Silica Nanoparticles Modulate Tumor Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as pharmacological agents and immune checkpoint blockade, often result in significant toxic effects and limited efficacy due to poor penetration in solid tumors and off-target effects, failing to eliminate all cancer cells and leading to tumor recurrence.
Innovation Solution
Administration of ultrasmall silica-based nanoparticles, such as C′ dots, which induce favorable changes in the tumor microenvironment by activating macrophages and modulating the immune profile without cytotoxicity to normal tissues, potentially combined with checkpoint blockade therapy or radiotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pharmacological agents are used to target cancer cells, then cancer cells are killed through cytotoxicity, but significant toxic effects occur on normal tissues
Solution Approach 1:
The patent applies local quality by designing nanoparticles with tumor-specific targeting capabilities (e.g., through surface functionalization with antibodies or peptides that bind to tumor markers) and by exploiting the enhanced permeability and retention effect in tumors. This allows the nanoparticles to accumulate preferentially in tumor tissue while minimizing exposure to normal tissues, thus achieving cancer cell killing with reduced systemic toxicity.
Solution Approach 2:
The nanoparticle serves as an intermediary carrier that delivers cytotoxic payloads selectively to cancer cells. The nanoparticle core (e.g., silica-based) acts as a vehicle that can be functionalized with targeting ligands and loaded with therapeutic agents, mediating the interaction between the treatment and the tumor while protecting normal tissues from direct exposure to cytotoxic drugs.
2Reliability
If immune checkpoint blockade is used to enhance immune response, then dramatic responses are achieved in hard-to-treat tumors, but off-target effects occur in immunosuppressed tumor microenvironments
Solution Approach 1:
The nanoparticle formulation enables local quality by providing tumor-specific targeting through surface functionalization (e.g., conjugation with antibodies against tumor markers or peptides that bind to tumor cell surface proteins). This ensures that the immune-modulating effects are concentrated at the tumor site rather than systemically, reducing off-target effects in the tumor microenvironment while maintaining effective immune activation.
Solution Approach 2:
The patent applies parameter changes by modulating the nanoparticle properties (such as size, surface charge, and functionalization) to optimize their interaction with the tumor microenvironment. By adjusting these parameters, the nanoparticles can enhance immune response specifically in the tumor context without triggering inappropriate immune activation elsewhere, thus reducing off-target effects.
3Reliability
If higher concentrations of nanoparticles are administered to induce ferroptosis, then tumor cell death occurs, but cytotoxicity to normal tissues increases
Solution Approach 1:
The nanoparticle system achieves local quality by exploiting the enhanced permeability and retention effect, where nanoparticles of specific size (e.g., 1-100 nm) accumulate preferentially in tumor tissue due to leaky vasculature and impaired lymphatic drainage. This passive targeting, combined with active targeting through surface functionalization, ensures high local concentration in tumors while maintaining lower concentrations in normal tissues, enabling ferroptosis induction with reduced systemic cytotoxicity.
Data Source
AI summary
Described herein are methods of treating cancer by inducing favorable effects on tumor microenvironment (e.g., including macrophage polarization, cytokine profile, and/or immunophenotype) via administration of nanoparticles (e.g., silica-based ultra-small nanoparticles and nanoparticle conjugates such as nanoparticle drug conjugates). In certain embodiments, the methods may be used in concert with, or as part of, checkpoint inhibition therapy (e.g., anti-PD1) or radiotherapy, or a combination of both radiotherapy and checkpoint inhibitor therapy.